Previous 10 | Next 10 |
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, annou...
2024-03-06 13:40:59 ET More on Iterum Therapeutics Iterum meets main goal in late trial for uUTI treatment with oral sulopenem Seeking Alpha’s Quant Rating on Iterum Therapeutics Historical earnings data for Iterum Therapeutics Financial information fo...
Resubmission of NDA is On Track for First Half of Q2 24 Extended Cash Runway into 2025 DUBLIN, Ireland and CHICAGO, March 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation ora...
2024-01-30 10:22:18 ET Read the full article on Seeking Alpha For further details see: Iterum meets main goal in late trial for uUTI treatment with oral sulopenem
2024-01-30 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections PR Newswire Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin ® ; Demonstrated Sta...
2023-12-04 08:29:21 ET More on Iterum Therapeutics Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript Historical earnings data for Iterum Therapeutics Financial information for Iterum Therapeutics For further details see: Iterum Therapeutics ...
Iterum Therapeutics PLC (NASDAQ: ITRM) is one of today's top gainers. The company's shares have moved 0.75% on the day to $0.68. Iterum Therapeutics PLC, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United State...
2023-11-28 11:49:39 ET More on Iterum Therapeutics Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript Historical earnings data for Iterum Therapeutics Financial information for Iterum Therapeutics For further details see: Iterum Therapeutics ...
2023-11-28 10:00:04 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Seelos Therape...
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharma...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...